Psychedelic Use, Cannabis Co-Use, and Prostate Cancer in Older Adults
Among men 50 and older, exclusive psychedelic use was associated with higher odds of prostate cancer, while those who used both psychedelics and cannabis had significantly lower odds than psychedelic-only users.
Quick Facts
What This Study Found
Exclusive classic psychedelic use was associated with 2.62 times higher odds of prostate cancer diagnosis compared to non-users. Among adults 65 and older, the association was even stronger (AOR=3.60). Notably, psychedelic-only users had 4.58 times higher odds than those who used both psychedelics and cannabis, suggesting a potential modifying role of cannabis co-use.
Key Numbers
19,460 males (weighted: 50.8 million). 3.9% reported prostate cancer. Psychedelic-only vs non-users: AOR=2.62 (p<0.01). Ages 65+: AOR=3.60 (p<0.01). Psychedelic-only vs co-users: AOR=4.58 (p<0.01).
How They Did This
Analysis of 19,460 males aged 50+ from the 2015-2019 National Survey on Drug Use and Health. Participants were categorized as cannabis-only users, psychedelic-only users, co-users, or non-users. Multivariable logistic regression adjusted for sociodemographic, behavioral, and clinical covariates.
Why This Research Matters
This is the first study to examine associations between psychedelic and cannabis use patterns and prostate cancer. The finding that cannabis co-use may modify the psychedelic-cancer association is novel and generates hypotheses for further research.
The Bigger Picture
While the study cannot determine causation, the protective-appearing pattern of cannabis co-use is consistent with preclinical research suggesting cannabinoids may have anti-tumor properties. However, numerous confounders could explain these associations.
What This Study Doesn't Tell Us
Cross-sectional design cannot establish causation. Self-reported substance use and cancer diagnosis. Lifetime use measures do not capture timing, dose, or frequency. Many potential confounders exist, including healthcare-seeking behavior.
Questions This Raises
- ?What biological mechanism could explain a psychedelic-prostate cancer link?
- ?Does cannabis genuinely modify cancer risk, or is this a confounding artifact?
- ?Would prospective studies confirm these associations?
Trust & Context
- Key Stat:
- 4.58x higher prostate cancer odds for psychedelic-only vs co-users with cannabis
- Evidence Grade:
- Preliminary: cross-sectional survey data with self-reported measures, unable to establish causation or control for many potential confounders
- Study Age:
- Published in 2025 using 2015-2019 NSDUH data
- Original Title:
- Association between lifetime co-use of classic psychedelics and cannabis and prostate cancer diagnosis among US adults 50 years and older.
- Published In:
- Scientific reports, 16(1), 609 (2025)
- Authors:
- Baral, Amrit(4), Pan, Yue(2), Hlaing, WayWay M, Garcia-Romeu, Albert, Pinheiro, Paulo S, Vidot, Denise C
- Database ID:
- RTHC-06009
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
Does cannabis protect against prostate cancer?
This study cannot answer that question. It found that men who used both psychedelics and cannabis had lower prostate cancer odds than psychedelic-only users, but this is a cross-sectional association that could be explained by many factors other than a direct protective effect.
Why would psychedelic use be associated with prostate cancer?
The study identified this novel association but could not determine why it exists. Possible explanations include confounding by other factors, differences in healthcare-seeking behavior, or biological mechanisms that have not yet been studied.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06009APA
Baral, Amrit; Pan, Yue; Hlaing, WayWay M; Garcia-Romeu, Albert; Pinheiro, Paulo S; Vidot, Denise C. (2025). Association between lifetime co-use of classic psychedelics and cannabis and prostate cancer diagnosis among US adults 50 years and older.. Scientific reports, 16(1), 609. https://doi.org/10.1038/s41598-025-30172-5
MLA
Baral, Amrit, et al. "Association between lifetime co-use of classic psychedelics and cannabis and prostate cancer diagnosis among US adults 50 years and older.." Scientific reports, 2025. https://doi.org/10.1038/s41598-025-30172-5
RethinkTHC
RethinkTHC Research Database. "Association between lifetime co-use of classic psychedelics ..." RTHC-06009. Retrieved from https://rethinkthc.com/research/baral-2025-association-between-lifetime-couse
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.